Introduction
Human cancer is a heterogeneous disease that can vary widely in clinical outcome and therapeutic response. This heterogeneity is likely to reflect the accumulation of numerous genetic aberrations and influences of the tumour microenvironments acquired throughout the multistage progression of cancer (Sander, 2000) . Various clinical and pathological characteristics have served as important tools to classify and stratify different tumour groups with respect to their prognosis and treatment outcomes. However, there is always a need to improve the resolution of such analyses.
Microarray expression analysis is a powerful technique for determining the coexpression of thousands of genes. Such studies can quickly yield a genome-wide description of mRNA expression in a given cell or tissue corresponding to a given physiological or pathological condition. Applying gene expression analysis to identify genes that are commonly deregulated in different tumour types may therefore facilitate identification of targets for the early diagnosis of cancer and the identification of clinically relevant biological targets associated with histological heterogeneity. In recent studies, global gene expression analysis of various human tumours has facilitated the identification of gene signatures related to tumour classification (Alizadeh et al., 2000) , disease outcome (Beer et al., 2002; Chen et al., 2007; Wang et al., 2007) , response to therapy (Thuerigen et al., 2006; Del Rio et al., 2007) and novel therapeutic targets (Bonavida, 2007) . One of the key remaining challenges for genome-wide gene-expression profiling is the assay of genes with rare transcripts. Approaches featuring high throughput and high sensitivity for detecting low-expression transcripts are urgently needed for functional genomic studies.
Suppression subtractive hybridization (SSH) is a global PCR-based, cDNA subtraction technique that facilitates the identification of genes that are differentially regulated between two complex biological systems (Diatchenko et al., 1996) . This procedure involves two successive tester-driver hybridization steps, which lead to normalization of tester-specific molecules, thus allowing the subsequent enrichment of low abundance, tester-specific transcripts. Accordingly, SSH offers a simple and reliable strategy to systematically identify cancer type-specific transcripts. To provide a highthroughput platform for the identification of differentially expressed genes, cDNA libraries were constructed with the differentially expressed cDNA clones isolated following SSH. Once printed on chips, these cDNA clones served as probes to screen tumour or normal tissue samples that were hybridized as targets (Lee et al., 1991; Amatscheck et al., 2004) . However, the main drawback of this approach is that the results are directly dependent on the signal level from the targets rather than the probes. Hence, the original molecular complexity of the samples represented by the subtracted library was often lost, rendering this approach ineffective for the detection of genes with low level of expression. Furthermore, cDNA spotted array experiments lack reproducibility and are difficult to quantitate (Russo et al., 2003; Draghici et al., 2006) .
Gene profiling with the Affymetrix oligonucleotide arrays offers an alternate platform that is more robust and permits the quantitation of mRNAs simultaneously (Lipshutz et al., 1999) . Despite its advantages, oligonucleotide arrays have not been widely used in conjunction with SSH due to difficulties in generating antisense RNA from the subtracted cDNAs. Here we report a modification of the conventional SSH methodology that allows efficient generation of antisense RNA following SSH to enable their characterization with Affymetrix oligonucleotide arrays. To differentiate our method from the conventional SSH, we termed it modified SSH (mSSH). Here, we present evidence to demonstrate that mSSH, together with oligonucleotide arrays, enhance the identification of low abundance transcripts that are tumour specific. Specifically, we are able to demonstrate the enrichment of low abundance tumourspecific transcripts for human hepatocellular carcinoma (HCC), breast carcinoma and nasopharyngeal carcinoma (NPC) with this strategy.
Results mSSH depletes over 90% of the transcripts in the tumour samples To identify differentially upregulated tumour-specific genes, forward subtractions with tumour RNA as tester and normal RNA as driver were performed. Five independent mSSH runs were performed with five independent pairs of human HCC biopsies and their corresponding histological normal tissues used as tester and drivers (see Materials and methods). Routinely, 80 mg of cRNA could be obtained from a typical subtracted sample. Unidirectional cRNAs generated from the subtracted cDNA were hybridized to Affymetrix HG U133A and U133B oligonucleotide probe arrays (Figure 1) .
To assess the efficiency of mSSH and to compare the nature of the transcripts with or without mSSH, cRNAs from the same five HCC biopsies and their corresponding five normal tissues were prepared individually and hybridized directly to the Affymetrix HG U133A and B arrays without subtraction. These results were compared with those obtained from mSSH using identical HCC tumour and normal samples. Without mSSH, the average total number of probe sets detected for the five HCC tumour biopsies L49, L52, L53, L57 and L60 was 14 810, or 33% of the total available probe sets on the Affymetrix HG U133A and B probe arrays (Table 1) . Following mSSH, the total number of probe sets detected was reduced to approximately 1778, or 4% of the total available probe sets on the Affymetrix HG U133A and B arrays. Together, there was a 90% reduction in the number of probe sets after subtraction.
A total of 1944, 1716, 2036, 1479 and 1714 probe sets could be detected with Affymetrix HG U133 sets following mSSH for sample L49, L52, L53, L57 and L60, respectively (Table 1 ). When the presence or absence of these transcripts were analysed using direct hybridizations without mSSH, it was determined that 732 (39%), 755 (44%), 836 (42%), 693 (47%) and 673 (41%) probe sets were classified as absent for L49, L52, L53, L57 and L60, respectively. These probe sets were therefore 'lost' when conventional expression profiling studies had been performed.
To confirm the efficacy of mSSH, we analysed the 100 housekeeping genes available on the Affymetrix HG U133A and B probe arrays. Following mSSH, only 2 of the 100 housekeeping genes could be detected in the subtracted HCC samples. These two genes were the ribosomal protein 4 (RLP4) and the anaphase promoting complex subunit 5 (APC5). The efficiency of subtraction following mSSH for the 100 housekeeping genes was also confirmed to be over 90%. In a follow-up analysis, two housekeeping genes, b-actin and glyceraldehydes-3-phosphodehydrogenase (GAPDH), were used as internal references to demonstrate that RLP4 and APC5 which had been detected in the subtracted samples were in fact upregulated in HCC using real-time PCR and independent HCC samples.
mSSH amplified the signals of low abundance tumour-specific transcripts Prior to mSSH, the distribution of the signal intensities following hybridization tended to conform to a normal distribution (Figure 2 ). However, following mSSH, the overall intensities of the signals were both shifted and skewed towards high levels. Specifically, for the five pairs of HCC samples examined, the median of the signal intensities detected was approximately 767 before mSSH, in comparison to 1516 after mSSH (Figure 2 ).
For a detailed analysis, signal intensities of all the probe sets detected after mSSH were traced back to their original signal obtained without mSSH. Specifically, for sample L49, 916 out of 1892 probe sets were detected in the signal range 0-500 before mSSH. Following mSSH, only 26 of these 916 probe sets (2%) remained in the same 0-500 signal range (Table 2a ). The signal intensities for the other 880 probe sets shifted to higher levels following mSSH: 257 probe sets (20%) were in the signal range 501-1000, 583 probe sets (62%) had signals in the range 1001-5000, 23 probe sets (5%) had signals in the range 5001-10 000 and 27 probe sets (11%) had signals over 10 000. Similar signal amplification could be detected for samples L52, L53, L57 and L60 (Supplementary Data 1). Thus, mSSH appears to amplify the intensity of detectable signals for tumour-specific transcripts that were originally of low signal intensities.
A summary of the change of signal intensities before and after mSSH of all the five samples is tabulated in Table 2b . On average, 51% of the probe sets yielded signal intensities between 0 and 500 before mSSH and only 3% of the probe sets had signal intensities in this range following mSSH. Interestingly, no probe set presented a signal intensity over 100 000 before mSSH, whereas more than 2% of the probe sets were detected with signal intensity more than 100 000 after mSSH. The Figure 1 Schematic representation of the mSSH procedures. Five independent modified suppression subtractive hybridization (mSSH) runs were performed with five independent pairs of human hepatocellular carcinoma (HCC) biopsies as testers and their corresponding histological normal tissues as drivers. Prior to digestion with Rsa1, the cDNAs ranged in size from 0.5 to 10 kb, whereas following digestion, majority of the cDNAs were between 0.1 and 2 kb in size. Tumour-specific fragments were subsequently generated by primary PCR and secondary nested PCR using tester-specific fragments obtained after two cycles of hybridization between tester and driver cDNAs. By inserting the T 7 -promoter sequence at the 5 0 end of the noncoding cDNA strand during first strand cDNA synthesis, unidirectional antisense RNAs could be synthesized from the subtracted cDNAs.
Identification of common and tumour type-specific transcripts BH Liu et al background signals remained relatively low (o100) for all five HCC samples studied, before and after mSSH.
Identification of differentially expressed cancer type-specific transcripts After demonstrating that mSSH could permit the identification of transcripts that are of low abundance, we then proceeded to study the transcripts obtained after mSSH for different tumour types, with the objective of identifying genes that are both frequently and specifically deregulated in these different malignancies. Such knowledge has the potential to facilitate the identification of targets for cancer diagnosis and therapeutic treatments. For this purpose, in addition to the five pairs of HCC samples studied above, five breast cancer biopsies and four NPC cancer biopsies were also employed individually for mSSH using the corresponding adjacent normal breast tissues as the drivers for breast cancer tissues and pooled normal nasal tissues as the driver for NPC as described in Materials and methods. After mSSH, the three data sets were comparatively analysed to identify gene expression patterns that were unique and common to each tumour type. Data included in the analysis were required to fulfill the following criteria. For each cancer type, a probe set would only be considered as consistently positive and be included in our analyses if the set was present in more than 70% of the samples studied. The data obtained were then further classified into specific cancer subgroups. A probe set would be classified as 'specific' for a tumour type when it was present in over 70% of the number of samples studied for that particular tumour type (NX4 for HCC and breast cancer, and NX3 for NPC), and was absent in more than 80% of the other types of cancers studied (NX7). Similarly, a probe set would be considered to be upregulated in two types of cancers if it was present in over 70% of the number of samples for the two types of cancers studied and was absent in more than 80% of the number of samples for the third type of cancer studied. Probe sets that were present in greater than 70% of all subtracted samples were considered as common probe sets for all three tumour types, that is, HCC, breast carcinoma and NPC. Probe sets that failed to meet any of the aforementioned criteria were excluded from subsequent analyses.
After the filtering processes, 48 probe sets were classified as HCC specific, 45 as breast carcinoma specific and 83 as NPC specific. A further 115 probe sets were simultaneously upregulated in all three cancer types (Figure 3a) . Clustering analysis was used to examine the expression patterns of these cancer typespecific genes in all subtracted samples. As depicted in Figure 3b , the three clusters did not overlap with each other. These genes, together with their functional annotations, are listed in Supplementary Data 2. A combined total of 291 tumour type-specific and common genes identified by mSSH were submitted to the Cancer Genome Anatomy (CGAP) Serial Analysis Genome Expression (SAGE) database (Brentani et al., 2003) to independently analyse their relative abundances. Of the identified transcripts, 269 were listed in the cancer SAGE database (Figure 3c ). Over 70% of the 269 transcripts were found to be of low abundance, whereas less than 4% of the transcripts identified were of high abundance. This comparison both confirmed and extended our conclusion that mSSH can preferentially enrich low abundance transcripts.
Consistent with the mSSH results, validation of the 10 transcripts with the highest expression after mSSH by reverse transcription (RT)-PCR confirmed that all but two of the genes identified (204954_s_at and 235402_s_at) were preferentially expressed in HCC (Figure 3d (i) ). Similarly, RT-PCR analysis of the top 10 expressed genes among the 115 common cancer type transcripts demonstrated that they were all upregulated in each of the three types of cancers studied (Figure 3d (ii)). When clustering analysis were performed, on a larger cohort of patients using the 48-gene member 80  100  125  160  200  250  320  400  500  630  800  1000  1250  1600  2000  2500  3200  4000  5000  6300  8000  10000  20000  30000  50000  100000  200000  300000  400000  500000  500000   60  80  100  125  200  250  320  400  500  630  800  1000  1250  1600  2000  2500  3200  4000  5000  6300  8000  10000  20000  30000  50000  100000  200000  300000 400000 Figure 2 Distribution of signal intensities of the probe sets detected before and after modified suppression subtractive hybridization (mSSH). The signal distributions of five liver samples were plotted with variances and medians indicated.
Identification of common and tumour type-specific transcripts BH Liu et al HCC-specific signature, 24 new independent liver samples were correctly segregated into clusters that separate 12 tumour biopsies and 12 normal samples (Figure 3e (i) ). Similarly, with the 45-member breast carcinoma-specific signature, 28 independent breast samples comprising 18 tumour and 10 normal samples were correctly segregated (Figure 3e (ii)); while the 83-member NPC-specific signature was able to segregate an independent 21 samples into 14 NPC tumour biopsies and 7 normal biopsies (Figure 3e (iii) ). The 115 transcripts that could be identified in all three tumour types following mSSH were also able to segregate most of the three different types of cancer studied from the normal tissues when subjected to clustering analysis (Figure 3f (i), (ii), and (iii)). These data confirmed that both the common and unique cancer-specific transcripts identified with mSSH were biologically relevant.
Discussion
Suppression subtractive hybridisation is a PCR-based cDNA subtraction technique. A key feature of this method is the simultaneous normalization and subtraction steps. The normalization step equalizes the abundance of DNA fragments within the target population, and the subtraction step excludes sequences that are common to the two populations being compared. Specific amplification of genes with SSH has allowed identification of small molecular differences between closely related biological systems. However, the comprehensive characterization and quantitation of subtracted cDNA clones following SSH is often technically laborious, thus severely limiting its utility. On the other hand, profiling methods with oligonucleotide arrays do not provide the flexibility to discern subtle changes between two biological populations. The present mSSH strategy combines the advantages of SSH and Affymetrix oligonucleotide probe arrays to enable global comparison of subtracted cDNAs without mass cloning and sequencing. Two specific modifications were made to conventional SSH to allow the generation of uni-directional cRNA from the subtracted cDNA. In contrast to conventional SSH method where the T 7 -promoter is introduced during the adaptor ligation step, our protocol incorporates the T 7 -RNA promoter into the 5 0 end of the noncoding DNA strand during first-strand synthesis (Figure 1 ). This modification overcomes the limitation of incorporating T7-promoter to both coding and noncoding cDNA, which would result in a mixed population of RNA following in vitro transcription. Secondly, we have employed the SP6-promoter as the adaptor sequence in place of the T 7 -promoter used in conventional SSH (Figure 1 ). Our modified SSH methodology is able to generate a single antisense RNA population that can be analysed with oligonucleotide arrays, with minimal background noise.
Human HCC, breast carcinoma and NPC are among the most common and lethal human malignancies. Few studies have focused on genetic similarities and differences between these tumour types. We have employed mSSH in combination with Affymetrix oligonucleotide Each row designates the number of probe sets detected for that given signal range before mSSH whereas each column represented the number of probe sets detected after mSSH for the given signal range.
Identification of common and tumour type-specific transcripts BH Liu et al arrays to compare the gene expression profiles of these cancers. Following mSSH, over 90% of the common transcripts between tumour and normal tissues were subtracted. More importantly, most of the probe sets identified following mSSH represented low abundance transcripts (Table 2 ). These transcripts would have been registered as not significantly different from the background and therefore excluded from further analysis in conventional gene profiling experiments (Qin et al., 2006) . This observation was further confirmed when we compared these transcripts to the SAGE database and demonstrated that over 70% of the transcripts obtained after mSSH were indeed classified as low abundant species (Figure 3c) . Many of the transcripts identified by mSSH represent either unknown genes or genes with no known function. For the HCC-specific transcripts, some of the corresponding genes are associated with pathways related to fatty acid metabolism (APOA2, HAO2, ECH1), signal transduction (DOK1, DYRK1B) and ion transport (CATSPER2, SFXN2). Two of the genes identified by mSSH have also been previously reported to be related to HCC: SIP1 identified by quantitative RT-PCR (Comijin et al., 2001) , and APOA2 identified by microsatellite DNA studies (Tsopanomichalou et al., 1999) . Several of the genes identified, including SERPI-NA1, ALB, AZGP1, APOA2 and CYP8B1, are known to be regulated by the liver-specific transcription factor HNF4a (Odom et al., 2004) , while the transcripts SEC14L2, DDR2 and ZYX identified by mSSH are reported to be regulated by p53. These findings are consistent with the well-documented role of p53 in liver carcinogenesis (Shiota et al., 1997; Kirk et al., 2005) .
For the breast cancer-specific transcripts, several genes related to Cathepsin B (CTSB) were identified, including ITGB1, FAU and SIGLEC1. CTSB encodes a lysosomal cysteine protease, which degrades the basement membrane and extracellular matrix. It has been ÀDDCt comparing each tumour samples to its normal. Green shows higher expression in normal; red shows higher expression in tumour. (e) Unsupervised hierarchical clustering analysis performed on new independent tumour samples using (i) 48 HCC-specific probe sets against 24 liver samples, (ii) 45 breast cancer-specific genes against 28 breast samples and (iii) 83 NPC-specific probe sets against 21 nasopharynx samples. Blue shows normal samples; Red shows cancerous samples. (f) Unsupervised hierarchical clustering analysis using the samples in (e) and the 115 common probe sets that are upregulated in all three cancer types.
reported to play an active role in determining the invasiveness of breast cancer (Lah et al., 2000) . In contrast, the NPC-specific transcripts gave a prominent immunological fingerprint. Among these are CD59, HLA-A, TAL-1, CD-74, EDNRB and LGALS1. It is well known that T-cell activation plays an important role in the pathogenesis of NPC and the tumour microenvironment (Young and Rickinson, 2004) . Moreover, a large proportion of these genes are implicated in the NFKB1 pathway. Amongst them, CD59, RAC2 and UBE2L3 which are regulated by NFKB; EDNRB, SMARCD1 and LGALS1 by JUN; MAT2A and EPOR by STAT1; and MAT2A, RAC2 and HLA-A by SP1. These various transcription factors are known to contribute to the transforming potential of the Epstein-Barr virus , which is a well-documented aetiological factor for NPC (Young and Murray, 2003; Thornburg et al., 2006) . This study also identified the signalling and metabolic pathways that are distinct for each cancer type. For example, some of the genes identified from the HCC-specific transcripts are associated with pathways related to fatty acid metabolism, signal transduction and ion transport while the NPCspecific signature gives a prominent immunological association. Despite having heterogeneous changes in gene expression across different tissues, our study demonstrated the presence of a common pool of 115 genes implicated in the emergence and progression of these three different types of human cancers.
Identification of genes that are both selectively expressed and common for human HCC, breast carcinoma and NPC would prove invaluable in furthering our understanding of the molecular carcinogenesis processes underlying these tumours and eventually aid in their clinical prevention, diagnosis and treatment.
Materials and methods

Clinical specimens
All tissue biopsies studied were from the Tissue Repository, National Cancer Centre Singapore, after obtaining approvals from both the Tissue Repository Management Committee and the Institutional Ethics Committee. Biopsies were collected from patients only after informed consents were given. Cancer tissues and adjacent noncancerous tissues were collected from five patients with HCC (HBV þ ) and five patients with invasive carcinoma of the breast: three with infiltrating ductal carcinoma, one with infiltrating lobular carcinoma and one with medullary carcinoma of the breast. The biopsies collected were immediately snap frozen in liquid nitrogen. Biopsies from four patients diagnosed with undifferentiated NPC (WHO Type III) as well as five nasopharyngeal biopsies that are histologically negative for NPC were also collected. All NPC biopsies were obtained as endoscopic bites and preserved immediately in RNAlater (Ambion/Applied Biosystems, Foster City, CA, USA). The histology of all the samples studied was confirmed by qualified pathologists. For the HCC and breast cancer samples, they were ascertained to consist of more Identification of common and tumour type-specific transcripts BH Liu et al than 70% of the tumour tissues, and the normal samples were free of tumour cells. For the NPC samples, independent pathology assessment was not possible due to the small size of the specimens. However, to rule out molecular contributions from nontumourous components as much as possible, the normal samples were obtained from immune tissues of suspected NPC, but histologically normal cases. Five specimens that were histologically negative for NPC were pooled and employed as normal nasal epithelial tissues for mSSH.
Suppression subtractive hybridization mSSH was employed to isolate mRNA differentially present in the target tumour biopsies (Figure 1) . RNA was extracted from tissue biopsies using Trizol reagent (Invitrogen Corp., Carlsbad, CA, USA). Purified total RNA (1 mg) was employed for the first strand synthesis using Clontech SMART PCR cDNA Synthesis Kit and 20 cycles of long distant-PCR was employed to synthesize double strand cDNA. mSSH was performed with the aid of the Clontech PCR-Select cDNA Subtraction Kit except for the use of four customized primers and adaptors as illustrated in Figure 1 . Tester and driver samples were digested separately with Rsa1 and ligated with the SP6 promoter adaptors. Ligation efficiency was checked using our customized PCR primer 1 and the primer for 3 0 GAPDH, as described in the manufacturer's protocol. Subsequent PCR amplification of tester-specific fragments was performed using PCR primer 1 as illustrated in Figure 1 . Procedures for mSSH and differential hybridization were essentially the same as those described in the manufacturer's instructions except the driver-to-tester ratio in the second hybridization was 2 instead of 1. The primary PCR cycling conditions were as follows: an incubation of 75 1C for 5 min followed by a total of 27 cycles at 94 1C for 30 s, 60 1C for 30 s and 72 1C for 1.5 min. Secondary PCR cycling involved a similar program, but with an annealing temperature of 65 1C.
Array hybridization and data analysis Four separate secondary PCR reactions were performed after mSSH. The PCR products were pooled and purified using a PCR Purification Kit (Qiagen, Chatsworth, CA, USA). The purified cDNA molecules were subsequently employed as templates for in vitro transcription. cRNA were then synthesized and labelled with biotinylated UTP and CTP using the Bioarray High Yield RNA Transcription Labeling Kit (Enzo Diagnostics, Farmingdale, NY, USA). The cRNA generated were employed for hybridization to the U133A and U133B gene arrays (Affymetrix, Santa Clara, CA, USA). The HCC database employed has been described previously (Wang et al., 2007) and the reported breast cancer database (Yu et al., 2006) was employed for the unsupervised hierarchical cluster analysis in Figure 3e . Further analyses were made using the Cluster and Treeview software (M Eisen, http://rana.lbl.gov/) and the Partek Genomic Suite (Partek Inc., MO, USA). The selected genes were annotated using the Affymetrix NetAffx analysis system (http://www.affymetrix.-com). Procedures for real time PCR analyses of selected genes have been described previously (Lau et al., 2007) .
